CRLX101: Phase Ib data

Data from the Phase Ib portion of an open-label, dose-escalation, U.S. Phase Ib/II trial in non-metastatic rectal cancer patients showed that 12 and 15 mg/m 2 CRLX101 plus chemoradiotherapy led to no ...